RxDoctor Payments DataLook up a doctor →

Chen Hoe Chow, MD

Cardiovascular Disease · Topeka, KSNPI 1679731939

Payments from drug & device makers

$186,989in general payments, 2019–2025

Across 730 payments — averaging $256.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$158K
  • Pfizer$25K
  • Abbott$1K
  • Novartis$557
  • AstraZeneca$405
  • Boehringer Ingelheim$344
  • plus $933 from 7 others

What the payments were for

  • Food & beverage$2,99391%
  • Education$3009%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$186,989 in reported general payments places this provider in the 95th percentile of 175 cardiovascular disease providers in Kansas.

See all cardiovascular disease providers in Kansas

Medicare billing

Part B allowed, 2024
$259,521
Medicare patients
1,895
Services billed
5,311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndaqelTafamidis Meglumine14$313,255
EliquisApixaban322$287,887
JardianceEmpagliflozin266$258,735
EntrestoSacubitril/Valsartan195$188,004
CamzyosMavacamten18$146,609
FarxigaDapagliflozin Propanediol175$142,170
XareltoRivaroxaban40$44,056
Tadalafil11$24,962
BrilintaTicagrelor22$14,825
Ambrisentan11$13,682
Repatha SureclickEvolocumab13$8,098
Metoprolol Succinate593$7,474
Atorvastatin Calcium649$6,917
Spironolactone530$3,241
Eplerenone25$2,660

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndaqel, Eliquis$25,250$601,142336 claims
Boehringer IngelheimJardiance$344$258,735266 claims
NovartisEntresto$557$188,004195 claims
AstraZenecaFarxiga, Brilinta$405$156,995197 claims
E.r. Squibb & Sons, L.L.C.Camzyos$141$146,60918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 175 cardiovascular disease providers in Kansas.

Other cardiovascular disease in Topeka

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →